Journal of Environmental and Public HealthVolume 2012 (2012), Article ID 460508, 10 pagesdoi:10.1155/2012/460508

Review Article

Mercury Toxicity and Treatment: A Review of the Literature

Robin A. Bernhoft1,2

¹Bernhoft Center for Advanced Medicine, Suite 208, 11677 San Vicente Boulevard, Los Angeles, CA 90049, USA²Los Angeles Center for Advanced Medicine, Brentwood Gardens Suite 208, 11677 San Vicente Boulevard, Los Angeles, CA 90049, USA

Received 4 July 2011; Accepted 1 November 2011

Academic Editor: Margaret E. Sears

Copyright © 2012 Robin A. Bernhoft. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Mercury is a toxic heavy metal which is widely dispersed in nature. Most human exposure results from fish consumption or dental amalgam. Mercury occurs in several chemical forms, with complex pharmacokinetics. Mercury is capable of inducing a wide range of clinical presentations. Diagnosis of mercury toxicity can be challenging but can be obtained with reasonable reliability. Effective therapies for clinical toxicity have been described.

1. Introduction

Mercury is a heavy metal of known toxicity, noted for inducing public health disasters in Minamata Bay, Japan [1] and in Iraq [2–4]. The clinical impact of smaller mercury exposures remains controversial. It exists in several forms: inorganic mercury, which includes metallic mercury and mercury vapor (Hg⁰) and mercurous (Hg₂ ⁺⁺) or mercuric (Hg⁺⁺) salts; and organic mercury, which includes compounds in which mercury is bonded to a structure containing carbon atoms (methyl, ethyl, phenyl, or similar groups). The biological behavior, pharmacokinetics, and clinical significance of the various forms of mercury vary with chemical structure. There is some interconversion in vivo between the various forms of mercury. Inhaled elemental mercury vapor, for example, is easily absorbed through mucus membranes and the lung and rapidly oxidized to other forms (but not so quickly as to prevent considerable deposition of elemental mercury in the brain). Methyl mercury is easily absorbed through the gut and deposits in many tissues, but does not cross the blood-brain barrier as efficiently as elemental mercury; however, on entering the brain it is progressively demethylated to elemental mercury [5]. Mercury salts, in contrast, tend to be insoluble, relatively stable, and poorly absorbed.

Human toxicity varies with the form of mercury, the dose and the rate of exposure. The target organ for inhaled mercury vapor is primarily the brain [5]. Mercurous and mercuric salts chiefly damage the gut lining and kidney [5], while methyl mercury is widely distributed throughout the body [5]. Toxicity varies with dosage: large acute exposures to elemental mercury vapor induce severe pneumonitis, which in extreme cases can be fatal [5]. Low-grade chronic exposure to elemental or other forms of mercury induces subtler symptoms and clinical findings, as discussed hereinafter.

There is considerable controversy about the clinical significance of exposure to the various forms of mercury and some disagreement regarding techniques for clinical assessment of mercury burden. This paper is intended to review published data on these issues and to assess published clinical experience using DMPS to remove mercury from the human body. Most of the authors cited hereinafter consider DMPS to be a stronger chelator than DMSA, with one exception citing evidence that DMSA is more effective at removing organic mercury [6]. This is a complicated issue. The absorption of DMPS and DMSA by ingestion is highly variable from one patient to the next; DMPS can be given intravenously, while DMSA cannot. DMPS is considerably safer than penicillamine or British anti-Lewisite, as discussed hereinafter. It is available for compounding in the United States and is available over the counter in Germany.

2. Sources of Mercury Exposure

Most human exposure to mercury is caused by outgassing of mercury from dental amalgam, ingestion of contaminated fish, or occupational exposure, according to the World Health Organization [7, 8].

Mercury exists in nature primarily as elemental mercury or as a sulfide and is found in the earth’s crust at approximately 0.5 parts per million. Atmospheric exposures occur from outgassing from rock or through volcanic activity. Human sources of atmospheric mercury include coal burning [9] and mining (mercury and gold in particular). Atmospheric elemental mercury settles in water, where it is converted by microorganisms into organic (methyl or ethyl) mercury, which is ingested by smaller creatures which are eventually consumed by larger fish. Fish at the top of the food chain (e.g., tuna, swordfish, or shark) may concentrate considerable mercury in their tissues.

Human mercury exposures occur chiefly [7, 8] through inhalation of elemental mercury vapor via occupational or dental amalgam exposure or through ingestion of mercury bonded to organic moieties (methyl, dimethyl, or ethyl mercury), primarily from seafood. Most human metallic mercury exposure comes from mercury vapor outgassing from amalgam fillings, at a rate of 2 to 28 micrograms per facet surface per day, of which about 80% is absorbed, according to the World Health Organization [7, 8] and Berglund et al. [10]. A less common source of mercury vapor is spilled mercury [11], and there is a report in the literature of Idiopathic Thrombocytopenic Purpura [12] caused by vacuuming spilled mercury (thereby producing a major acute exposure to mercury vapor).

Methyl and dimethyl mercury (organic mercury) usually originate from biological sources, chiefly fresh or salt water fish. Over three thousand lakes in the United States have been closed to fishing due to mercury contamination [5] and many species of ocean fish are also tainted with considerable concentrations of mercury [13].

3. Pharmacokinetics of Mercury Exposure

3.1. Inorganic Mercury

3.1.1. Elemental or Metallic (Hg⁰) Mercury

Approximately 80% of metallic mercury vapor outgassed from amalgams is absorbed through inhalation [10, 14, 15], compared with about 7 to 10% absorption of ingested metallic mercury [5], and about 1% absorption of metallic mercury through skin contact [5]. On entry to the body, mercury vapor has great affinity for sulfhydryl groups and bonds to sulfur-containing amino acids throughout the body. Mercury vapor is transported to the brain [16], either dissolved in serum or adherent to red cell membranes. Metallic mercury passes easily through the blood brain barrier [17] and through the placenta, where it lodges in the fetal brain [18]. Metallic mercury is, however, rapidly oxidized to mercuric mercury on entry to the blood stream [5], although not so quickly as to prevent considerable uptake by the central nervous system while still in the metallic form.

In addition to the brain [16, 19–26], metallic mercury is also deposited in the thyroid [5, 19, 21], breast [27], myocardium [28, 29], muscles [5, 21], adrenals [5], liver [5, 30–32], kidneys [5, 7, 8, 19, 20, 23, 30–32], skin [5, 7, 8], sweat glands [5], pancreas [5], enterocytes [5, 30], lungs [5, 23, 30], salivary glands [5], testes, and prostate [5] and may be associated with dysfunction of those organs. Mercury also has affinity for binding sites on the surface of T cells and for sulfhydryl groups influencing T cell function [33, 34]. Mercury deposits readily in placenta and fetal tissues and is found in breast milk. [5, 18, 31, 35]

Metallic mercury is largely excreted as mercuric mercury [5]. The excretory half lives of metallic and mercuric mercury vary widely, depending on the organ of deposition and redox state, with values ranging from a few days to several months [5], with some pools (e.g., CNS) having a half life exceeding several years [5]. Hair mercury does not correlate with brain content of metallic mercury [5]. These complexities make accurate assessment of body burden challenging (see Section 9 hereinafter).

3.1.2. Mercurous (Hg₂ ⁺⁺) Mercury

Mercurous mercury salt in the form of Hg₂Cl₂ (calomel) is poorly soluble in water and poorly absorbed by the intestine, although some portion is thought to undergo oxidation to more readily absorbable forms [36]. It is doubtful that mercurous mercury survives in the body, other than as a transitional form between metallic and mercuric mercury [5].

Some absorption evidently occurs, however, as calomel is occasionally associated with pink disease, or acrodynia.

3.1.3. Mercuric (Hg⁺⁺) Mercury

Historically, mercuric chloride (HgCl₂) was used as a preservative and for development of photographic film and was ingested accidentally or as a suicide measure. It is a component of some skin-lightening creams. Only about 2% of ingested mercuric chloride is absorbed initially [37], although it is believed that its corrosive effect on the intestine may increase permeability and, hence, absorption, with prolonged exposure [38]. Available data on skin penetration of mercuric mercury are insufficient to make quantitative comparison with ingestion or with metallic mercury.

Like metallic mercury, mercuric mercury in the bloodstream adheres to sulfhydryl groups on erythrocytes, metallothionein, or glutathione or is suspended in plasma [26]. Mercuric mercury does not cross the blood-brain barrier efficiently, but it does accumulate in quantity in the placenta, fetal tissues, and amniotic fluid [35]. Evidence exists showing transport of mercuric mercury via one or more amino acid transporters [39], particularly that for cysteine, which may account for accumulation in the brain [5]. Much of the body burden of mercuric mercury resides in the proximal convoluted renal tubule [40] bonded to metallothionein [41]. Significant deposition also occurs periportally in the liver [42] and lesser amounts in epithelial tissues, choroidal plexus, and testes.

Excretion of mercuric mercury is largely through urine and stool, although significant amounts are shed through sweat, tears, breast milk, and saliva [5, 43]. Half lives appear to be multiphasic, as with metallic mercury, with human studies suggesting an effective half life of 42 days for 80% of an oral tracer dose; the other 20% did not appear to have a measureable rate of excretion [44]. This may reflect demethylation to metallic mercury in the brain and other organs or mechanisms yet to be determined.

3.2. Organic Mercury Compounds

Most available data on organic mercury compounds refer to methyl mercury, which is a major source of human mercury exposure, is found naturally in fish, and is relatively stable. Ethyl mercury behaves in a similar fashion to methyl mercury at the cellular level, but with an excretory half life about one third as long [5].

Methyl mercury vapor is absorbed with similar (80%) efficiency as metallic mercury vapor [5]. Intestinal absorption of methyl mercury from fish is also fairly efficient, as is absorption through the skin [5]. On entry to the bloodstream, methyl mercury adheres to sulfhydryl groups, particularly to those in cysteine. Methyl mercury is deposited throughout the body, with equilibrium between blood and body occurring approximately four days after exposure [45]. Distribution to peripheral tissues seems to occur through one or more transporters, especially the cysteine transporter, probably adherent to the sulfhydryl group in cysteine [5].

Concentration of methyl mercury occurs in the brain, liver, kidneys, placenta, and fetus, especially in the fetal brain, as well as in peripheral nerves and bone marrow [5]. Deposited methyl mercury slowly undergoes demethylation to inorganic mercury [46].

The excretory half life of methyl mercury in man is about 70 days, with approximately 90% being excreted in stool. Some degree of enterohepatic circulation apparently occurs. Perhaps 20% of methyl mercury is excreted in breast milk, with the actual amount varying with severity of exposure [5]. Hair mercury reflects blood methyl mercury at the time of incorporation, but not elemental mercury [47], and hence is not a good index of total body burden [5], given the short half life of methyl mercury in blood.

Dimethyl mercury is also efficiently absorbed through the skin, and there is a reported death of a scientist caused by minimal skin contact [48].

4. Toxicity

4.1. Inorganic Mercury

4.1.1. Metallic Mercury Vapor

Mercury in all forms poisons cellular function by altering the tertiary and quaternary structure of proteins and by binding with sulfhydryl and selenohydryl groups. Consequently, mercury can potentially impair function of any organ, or any subcellular structure. The chief target organ of mercury vapor is the brain, but peripheral nerve function, renal function, immune function, endocrine and muscle function, and several types of dermatitis have been described [49].

With massive acute exposure to mercury vapor, erosive bronchitis and bronchiolitis potentially leading to respiratory failure may be accompanied by CNS symptoms such as tremor or erethism [50].

Chronic exposure to clinically significant doses of mercury vapor usually produces neurological dysfunction. At low-level exposures, nonspecific symptoms like weakness, fatigue, anorexia, weight loss, and gastrointestinal disturbance have been described [51]. Higher exposure levels are associated with mercurial tremor: fine muscle fasciculations punctuated every few minutes by coarse shaking. Erethism may also be observed: severe behavior and personality changes, emotional excitability, loss of memory, insomnia, depression, fatigue, and in severe cases delirium and hallucination [10]. Gingivitis and copious salivation have been described [5].

These symptoms may regress with cessation of exposure, but in many cases do not. Persistent neurological symptoms are common [52].

4.1.2. Mercurous Mercury

Calomel (Hg₂Cl₂) is still used in some regions of the world as a laxative. Although poorly absorbed, some is converted to mercuric mercury, which is absorbed, and induces toxicity as expected with mercuric mercury.

4.1.3. Mercuric Mercury

Acute poisoning with mercuric salts (typically HgCl₂) generally targets the gastrointestinal tract and the kidneys. Extensive precipitation of enterocyte proteins occurs, with abdominal pain, vomiting, and bloody diarrhea with potential necrosis of the gut mucosa. This may produce death either from peritonitis or from septic or hypovolemic shock. Surviving patients commonly develop renal tubular necrosis with anuria [53].

Chronic poisoning with mercury salts is rare, usually also involving concomitant occupational exposure to mercury vapor. Kidney toxicity involves either renal tubular necrosis or autoimmune glomerulonephritis, or both [53]. Immune dysfunctions include hypersensitivity reactions to mercury exposure, including asthma and dermatitis, various types of autoimmunity [54], and suppression of natural killer cells [55] and disruption of various other lymphocyte subpopulations [5].

Brain dysfunction is less evident than with other forms of mercury. Thyroid dysfunction seems associated with inhibition of the 5′ deiodonases, with decreased free T3 and increased reverse T3 [56]. Accumulation in the testicles appears to inhibit spermatogenesis [57]. Atrophy and capillary damage have been described in thigh muscle [58].

4.2. Organic Mercury

Methyl mercury reacts with sulfhydryl groups throughout the body, therefore potentially interfering with the function of any cellular or subcellular structure. Mercury is believed to interfere with DNA transcription and protein synthesis [59], including protein synthesis in the developing brain, with destruction of endoplasmic reticulum and disappearance of ribosomes [60]. Evidence suggests disruption of numerous subcellular elements in the central nervous system and other organs and in mitochondria; adverse effects have also been described on heme synthesis [61], cell membrane integrity in many locations [5], free radical generation [27, 62, 63], neurotransmitter disruption, and stimulation of neural excitoxins [5], resulting in damage to many parts of the brain and peripheral nervous system [5].

Methyl mercury has been associated with reduction in Natural Killer cell activity [64–67], as well as an imbalance in Th2 : Th1 ratios favoring autoimmunity [34, 68, 69]. Mercury is also possibly associated with disruption of DNA repair [5, 27]. The affinity of mercury for sulfhydryl groups of the mitochondrial oxidative phosphorylation complex [70] associated with destruction of mitochondrial membranes may contribute to chronic fatigue syndrome.

5. Clinical Presentation

5.1. Inorganic

5.1.1. Elemental (Metallic) Mercury

Acute exposure to a large quantity of mercury vapor induces pneumonitis, as discussed previously. Symptoms of low-grade chronic exposure are more subtle and nonspecific: weakness, fatigue, anorexia, weight loss, and gastrointestinal distress [5], sometimes referred to as micromercurialism [71]. At higher exposures, the mercurial fine tremor punctuated by coarse shaking occurs; erethism, gingivitis, and excessive salivation have also been described [5], as has immune dysfunction [34].

Objective findings include altered evoked potentials and decreased peripheral nerve conduction velocity [72]. Objective measures of short-term memory may be inversely correlated with urinary mercury in chloralkali workers [73]. Reduced color vision and visual acuity have also been observed [74]. Changes in coordination, tremor, mental concentration capacity, facial expression, and emotional state are also described [75], as are polyarthritis, various forms of dermatitis, and a syndrome mimicking pheochromocytoma [76].

Subtler clinical findings among dentists have been documented, including delayed reaction time, poor fine motor control, and deficits in mental concentration, vocabulary, task switching, and the One Hole test, as well as mood lability, all correlating with urinary mercury excretion [75]. Evidence also links elemental mercury to depression, excessive anger, and anxiety [77], as well as acute myocardial infarction, lipid peroxidation, and carotid atherosclerosis, in Finland [78]; the Finnish experience may possibly be explained by dietary selenium deficiency, since selenium antagonizes mercury toxicity. Other investigators, however, have described associations between mercury and hypertension, lipid peroxidation, ischemic heart disease, and stroke [79].

5.1.2. Mercuric Salts

Ingestion of mercuric chloride produces extensive precipitation of intestinal mucosal proteins, mucosal necrosis, generalized abdominal pain, bloody diarrhea, and shock. If the patient survives, acute renal failure may follow [5].

5.2. Organic Mercury

Methyl mercury and ethyl mercury produce similar signs and symptoms. Most published data refer to methyl mercury. Symptoms relate more to magnitude of methyl mercury retention than to the rate of deposition. Acute exposures tend to have a latency period of one or more weeks; once acquired, toxic doses are cleared slowly, if at all [5].

Massive prenatal poisoning may induce a form of cerebral palsy [5]. Lesser prenatal doses have been associated with neurodevelopmental delays and cognitive deficits [80–82].

Postnatal exposures generate a range of symptoms ranging from paresthesias, with lesser exposures, to ataxia, visual, auditory, and extrapyramidal impairments with moderate exposures and clonic seizures in more severe exposures, as in Minamata [1] and Iraq [2–4].

Objective physical findings are similar to those seen with elemental mercury exposure.

6. Laboratory Assessment of Mercury Exposure

Given the wide range of excretory half lives of the various mercury pools, discussion of laboratory assessment will combine the various forms into one discussion. It is important to recall that blood, hair, and urine mercury levels reflect recent exposure and do not correlate with total body burden [83–86]. Blood and urine levels correlate fairly well to each other, but not to total body burden [87]. With half life of all mercury pools in the blood estimated to be in the range of three to five days [88], during which either excretion or deposition in solid organs occurs, more accurate means of estimating body burden have been required.

That being said, the US federal biological exposure index (BEI) is currently set at 50 mcg/L urine. Aside from the obvious problems associated with basing a monitoring index on a measurement which only reflects current or recent exposure, and not overall body burden, several clinical studies show objective symptoms well below 50 mcg/L, with many proband values extending down into the low end of the reference range for urinary mercury excretion [75, 89–94], effectively rendering the US federal BEI useless for clinical or investigational purposes. Similar criticisms have been made of the EPA Reference Dose for methylmercury [95]. As summarized by Kazantzis, “it has not been possible to set a level for mercury in blood or urine below which mercury related symptoms will not occur” [96].

Because of these difficulties, provocation with a chelator has been proposed as providing a more reliable estimate of body burden, and DMPS (2,3 Dimercapto-1-Propanesulfonate) has been found by a number of investigators to provide a reliable estimate of body burden, safer than British Anti-Lewisite and more potent than DMSA [75, 97–101].

7. DMPS: Safety

DMPS is an analog of British Anti-Lewisite (BAL) with high affinity for mercury. Due to its superior safety, it has been widely used in Germany for the past fifty years and is available over the counter in that country. Protocols determining the pharmacokinetics of DMPS and evaluating its use for diagnostic purposes have been published in Germany [101], Sweden [102, 103], New Zealand [100], and Mexico [104] and in the United States [105–109].

Maiorino et al. [106] gave his volunteers DMPS 300 mg orally; over 90% of the absorbed DMPS was converted rapidly to disulfide forms. Published absorption of ingested DMPS varies from 39% [107] to 60% [110]. The excretory half life of unaltered DMPS was hours. The excretory half life of the disulfide forms of DMPS washours.

Hurlbut et al.’s [107] volunteers were given an unusually large dose of DMPS (3 mg/kg intravenously over 5 minutes). Two subjects had a transient 20 mmHg drop in systolic blood pressure during infusion, without other changes in vital signs. Excretory half life of unaltered DMPS ranged from 1.3 to 4.0 hours. Half life of the altered DMPS was from 19.8 to 37.5 hours.

In each of the cited studies, mercury output following provocation with DMPS correlated significantly with amalgam number and/or occupational or dietary exposure. There were no significant complications in any of the trials. Consequently, all the investigators but one [111] concluded that urine output provoked by DMPS represented a fair estimate of body burden.

8. DMPS: Efficacy

Each of the test trials cited in the previous section and others [112] showed statistically significant increases in urinary mercury output with administration of DMPS. With prolonged treatment, evidence of decreased body burden has been inferred [113].

Several controlled clinical trials support this conclusion. The largest was undertaken in the Phillippines in a gold mining area [114]. Workers in gold mining who sustained ongoing exposure to elemental mercury were compared to people living downstream who ate fish, which contained considerable methyl mercury, and to controls without significant known mercury exposure. Probands from the two exposed areas were chosen with elevated blood, urine and hair mercury levels, and appropriate symptoms (tremor, sleeplessness, memory loss, etc.)[115]; controls had normal levels and were asymptomatic.

One hundred six probands completed the fourteen-day trial with oral DMPS 400 mg per day. The only complication was an allergic rash in one patient, who was excluded from the trial. Blood mercury did not decrease during the trial, despite increases in urine mercury up to 85-fold.

Despite the short (fourteen-day) duration of the trial, significant improvements were observed in objective measures like hypomimia, Romberg test, tests for tremor and ataxia, pencil tapping, and Frostig visual perception. Most of the patients reported subjective improvement in memory, sleeplessness, metallic taste, fatigue, anxiety, and paresthesias. Treatment efficacy was similar in the metallic mercury group (miners) and in the methyl mercury group (downstream fish eaters). Similar results were presented in a parallel study by Drasch et al. [115].

A university case report from the United States of treatment of occupational exposures to mercury vapor [116] showed relief of muscle twitching, arthralgias, paresthesias, night sweats, weight loss, and excessive salivation following two weeks of oral DMPS 100 mg TID followed by DMPS 100 mg QID for an additional six weeks. Reduction of symptoms closely paralleled urine mercury output, which tapered over time.

9. Discussion

Mercury toxicity is not often included in the differential diagnosis of common subjective complaints such as fatigue, anxiety, depression, odd paresthesias, weight loss, memory loss, and difficulty concentrating, but these are the symptoms of low-grade chronic mercury exposure described by the investigators cited previously. Given the ability of the various forms of mercury to deposit in most parts of the human body, the range of symptoms potentially caused by mercury is quite large.

Animal studies linking mercury toxicity to neurodegenerative diseases [117, 118] raise clinical concern, as do a series of associations between mercury and neurodegenerative diseases in humans [119–123].

Mercury exposure is not insignificant according to WHO, as cited previously, and the NHANES reports suggest widespread exposure in the United States, especially among women [124, 125].

Diagnosis of mercury overload is difficult. The commonly used modalities (blood, urine, and/or hair levels) do not correlate with total body burden and offer little diagnostically useful information. Provocation with DMPS appears to offer a more accurate assessment of body burden.

Since provocation is safe and inexpensive, indications for provocation must rest on clinical grounds: does the patient have multiple, vague symptoms similar to those described in the mercury literature, without other plausible, and potentially reversible, explanation? Is there a significant history of mercury exposure: multiple amalgam fillings, high seafood intake, and history of multiple thimerosal-containing vaccinations or significant occupational exposures? Is there a family history of Alzheimer’s, Parkinson’s, or other diseases with postulated links to mercury exposure? Is there a history of known glutathione transferase (GST) polymorphisms, which decrease the body’s ability to clear heavy metals like mercury?

If so, then provocation with a chelator may be indicated. Published protocols [126–130] exist which call for provocation with DMPS with or without EDTA, in sequence. These are designed for safety, and for diagnostic breadth. DMPS has far better affinity for mercury than EDTA, but EDTA is more effective in removing lead, cadmium, nickel, and other toxic metals. Provocation with both gives a fuller picture of overall metal burden. Patients with GST enzyme abnormalities may also receive glutathione to expedite excretion of chelated metal. For unknown reasons, patients with GST polymorphisms tend to excrete mercury later in their course of treatment than other heavy metals [131]; this can sometimes produce early false negatives for mercury, due to preferential excretion of lead and other metals. All effective chelation protocols call for replacement of beneficial minerals, which are also removed by EDTA and DMPS.

There are currently no consensus criteria for the diagnosis of mercury overload, nor for overload of other toxic metals. Clinicians who specialize in this area generally consider a provoked urine metal output more than 2 standard deviations above the NHANES reference range a positive result.

Further research is required to clarify the relation between provoked urine results and clinical disease and to document clinical outcomes.

References

Environmental Health Department, Ministry of the Environment, Minimata Disease: The History and Measures, Ministry of the Environment, Government of Japan, Tokyo, Japan, 2002.

F. Bakir, S. F. Damluji, and I. Amin Zaki, “Methylmercury poisoning in Iraq: an interuniversity report,” Science, vol. 181, no. 4096, pp. 230–241, 1973.

S. B. Skerfving and J. F. Copplestone, “Poisoning caused by the consumption of organomercury dressed seed in Iraq,” Bulletin of the World Health Organization, vol. 54, no. 1, pp. 101–112, 1976.

T. W. Clarkson, L. Magos, and C. Cox, “Tests of efficacy of antidotes for removal of methylmercury in human poisoning during the Iraq outbreak,” Journal of Pharmacology and Experimental Therapeutics, vol. 218, no. 1, pp. 74–83, 1981.

M. Berlin, R. K. Zalups, and B. A. Fowler, “Mercury,” in Handbook on the Toxicology of Metals, G. F. Nordberg, B. A. Fowler, M. Nordberg, and L. T. Friberg, Eds., chapter 33, Elsevier, New York, NY, USA, 3rd edition, 2007.

H. V. Aposhian, “DMSA and DMPS—water soluble antidotes for heavy metal poisoning,” Annual Review of Pharmacology and Toxicology, vol. 23, pp. 193–215, 1983.

World Health Organization, “Inorganic mercury: environmental health criteria 118,” in International Programme on Chemical Safety, World Health Organization, Geneva, Switzerland, 1991.

M. Richardson, The Safety of Dental Amalgam, ISBN 0-662-24873-2, Minister of Health, Canada, 1996.

H. M. Boylan, R. D. Cain, and H. M. Kingston, “A new method to assess mercury emissions: a study of three coal-fired electric-generating power station configurations,” Journal of the Air and Waste Management Association, vol. 53, no. 11, pp. 1318–1325, 2003.

A. Berglund, L. Pohl, S. Olsson, and M. Bergman, “Determination of the rate of release of intra-oral mercury vapor from amalgam,” Journal of Dental Research, vol. 67, no. 9, pp. 1235–1242, 1988.

P. Zeitz, M. F. Orr, and W. E. Kaye, “Public health consequences to mercury spills: hazardous substances emergency events surveillance system, 1993–1998,” Environmental Health Perspectives, vol. 110, no. 2, pp. 129–132, 2002.

J. G. Schwartz, T. E. Snider, and M. M. Montiel, “Toxicity of a family from vacuumed mercury,” American Journal of Emergency Medicine, vol. 10, no. 3, pp. 258–261, 1992.

J. Burger, C. Jeitner, and M. Gochfeld, “Locational differences in mercury and selenium levels in 19 species of saltwater fish from New Jersey,” Journal of Toxicology and Environmental Health, vol. 74, no. 13, pp. 863–874, 2011.

F. N. Kudsk, “The influence of ethyl alcohol on the absorption of mercury vapour from the lungs in man,” Acta Pharmacologica et Toxicologica, vol. 23, no. 2, pp. 263–274, 1965.

J. B. Hursh, T. W. Clarkson, and M. G. Cherian, “Clearance of mercury (Hg-197, Hg-203) vapor inhaled by human subjects,” Archives of Environmental Health, vol. 31, no. 6, pp. 302–309, 1976.

D. W. Eggleston and M. Nylander, “Correlation of dental amalgam with mercury in brain tissue,” The Journal of Prosthetic Dentistry, vol. 58, no. 6, pp. 704–707, 1987.

G. F. Nordberg and F. Serenius, “Distribution of inorganic mercury in the guinea pig brain,” Acta Pharmacologica et Toxicologica, vol. 27, no. 4, pp. 269–283, 1969.

T. W. Clarkson, L. Magos, and M. R. Greenwood, “The transport of elemental mercury into fetal tissues,” Biology of the Neonate, vol. 21, no. 3, pp. 239–244, 1972.

G. Guzzi, M. Grandi, C. Cattaneo et al., “Dental amalgam and mercury levels in autopsy tissues: food for thought,” American Journal of Forensic Medicine and Pathology, vol. 27, no. 1, pp. 42–45, 2006.

J. W. Reinhardt, “Side-effects: mercury contribution to body burden from dental amalgam,” Advances in Dental Research, vol. 6, pp. 110–113, 1992.

L. Björkman, B. F. Lundekvam, T. Lægreid et al., “Mercury in human brain, blood, muscle and toenails in relation to exposure: an autopsy study,” Environmental Health, vol. 6, article 30, 2007.

D. Wenstrup, W. D. Ehmann, and W. R. Markesbery, “Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains,” Brain Research, vol. 533, no. 1, pp. 125–131, 1990.

M. Nylander, L. Friberg, and B. Lind, “Mercury concentrations in the human brain and kidneys in relation to exposure from dental amalgam fillings,” Swedish Dental Journal, vol. 11, no. 5, pp. 179–187, 1987.

J. Mutter, A. Curth, J. Naumann, R. Deth, and H. Walach, “Does inorganic mercury play a role in Alzheimer's disease? A systematic review and an integrated molecular mechanism,” Journal of Alzheimer's Disease, vol. 22, no. 2, pp. 357–374, 2010.

R. L. Siblerud, “The relationship between mercury from dental amalgam and mental health,” American Journal of Psychotherapy, vol. 43, no. 4, pp. 575–587, 1989.

T. W. Clarkson, J. Gatzy, and E. Dalton, UR-582, Division of Radiation Chemistry and Toxicology, University of Rochester Atomic Energy Project, Rochester, NY, USA, 1961.

M. E. Crespo-López, G. L. Macêdo, S. I. D. Pereira et al., “Mercury and human genotoxicity: critical considerations and possible molecular mechanisms,” Pharmacological Research, vol. 60, no. 4, pp. 212–220, 2009.

A. Frustaci, N. Magnavita, C. Chimenti et al., “Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction,” Journal of the American College of Cardiology, vol. 33, no. 6, pp. 1578–1583, 1999.

N. Matsuo, T. Suzuki, and H. Akagi, “Mercury concentration in organs of contemporary Japanese,” Archives of Environmental Health, vol. 44, no. 5, pp. 298–303, 1989.

L. J. Hahn, R. Kloiber, M. J. Vimy, Y. Takahashi, and F. L. Lorscheider, “Dental 'silver' tooth fillings: a source of mercury exposure revealed by whole-body image scan and tissue analysis,” FASEB Journal, vol. 3, no. 14, pp. 2641–2646, 1989.

M. J. Vimy, Y. Takahashi, and F. L. Lorscheider, “Maternal-fetal distribution of mercury released from dental amalgam fillings,” American Journal of Physiology, vol. 258, no. 4, pp. R939–R945, 1990.

G. Danscher, P. Horsted-Bindslev, and J. Rungby, “Traces of mercury in organs from primates with amalgam fillings,” Experimental and Molecular Pathology, vol. 52, no. 3, pp. 291–299, 1990.

P. Hultman, “Immunotoxicology of metals,” in Handbook on the Toxicology of Metals, G. F. Nordberg, B. A. Fowler, M. Nordberg, and L. T. Friberg, Eds., pp. 205–206, Elsevier, Amsterdam, The Netherlands, 3rd edition, 2007.

S. H. Park, S. Araki, A. Nakata et al., “Effects of occupational metallic mercury vapour exposure on suppressor-inducer (CD4+CD45RA+) T lymphocytes and CD57+CD16+ natural killer cells,” International Archives of Occupational and Environmental Health, vol. 73, no. 8, pp. 537–542, 2000.

T. Suzuki, T. I. Takemoto, S. Shishido, and K. Kani, “Mercury in human amniotic fluid,” Scandinavian Journal of Work, Environment and Health, vol. 3, no. 1, pp. 32–35, 1977.

Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th edition, 1990.

T. Norseth and T. W. Clarkson, “Intestinal transport of ²⁰³Hg-labeled methyl mercury chloride. Role of biotransformation in rats,” Archives of Environmental Health, vol. 22, no. 5, pp. 568–577, 1971.

K. Kostial, D. Kello, and S. Jugo, “Influence of age on metal metabolism and toxicity,” Environmental Health Perspectives, vol. 25, pp. 81–86, 1978.

T. Jansson, “Amino acid transporters in the human placenta,” Pediatric Research, vol. 49, no. 2, pp. 141–147, 2001.

R. Taugner, K. zum Winkel, and J. Iravani, “The localization of mercuric chloride concentration in the rat kidney,” Virchows Archiv, vol. 340, no. 4, pp. 369–383, 1966.

M. G. Cherian and T. W. Clarkson, “Radioactive mercury distribution in biological fluids and excretion in human subjects after inhalation of mercury vapor,” Archives of Environmental Health, vol. 33, no. 3, pp. 109–114, 1978.

M. Berlin and S. Ullberg, “Accumulation and retention of mercury in the mouse. I. An autoradiographic study after a single intravenous injection of mercuric chloride,” Archives of Environmental Health, vol. 6, pp. 589–601, 1963.

K. A. Björnberg, M. Vahter, B. Berglund, B. Niklasson, M. Blennow, and G. Sandborgh-Englund, “Transport of methylmercury and inorganic mercury to the fetus and breast-fed infant,” Environmental Health Perspectives, vol. 113, no. 10, pp. 1381–1385, 2005.

T. Rahola, T. Hattula, and A. Lorolainen, “The Elimination of ²⁰³Hg-methylmercury in man,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 27, supplement 116, p. 77, 1971.

T. G. Kershaw, T. W. Clarkson, and P. H. Dhahir, “The relationship between blood levels and dose of methylmercury in man,” Archives of Environmental Health, vol. 35, no. 1, pp. 28–36, 1980.

I. Suda and H. Takahashi, “Degradation of methyl and ethyl mercury into inorganic mercury by other reactive oxygen species besides hydroxyl radical,” Archives of Toxicology, vol. 66, no. 1, pp. 34–39, 1992.

M. Berglund, B. Lind, K. A. Björnberg, B. Palm, O. Einarsson, and M. Vahter, “Inter-individual variations of human mercury exposure biomarkers: a cross-sectional assessment,” Environmental Health, vol. 4, article 20, 2005.

D. W. Nierenberg, R. E. Nordgren, M. B. Chang et al., “Delayed cerebellar disease and death after accidental exposure to dimethylmercury,” New England Journal of Medicine, vol. 338, no. 23, pp. 1672–1676, 1998.

M. Berlin, Dental Materials and Health, Statens Offentliga Utredningar, Stockholm, 2003.

R. Garnier, J. M. Fuster, and F. Conso, “Acute mercury vapour poisoning,” Toxicological European Research, vol. 3, no. 2, pp. 77–86, 1981.

L. Friberg and G. F. Nordberg, Eds., Mercury in the Environment, CRC Press, Boca Raton, Fla, USA, 1972.

G. Baldi, E. C. Vigliani, and N. Zurlo, “Mercury poisoning in hat industry,” La Medicina del Lavoro, vol. 44, no. 4, pp. 160–199, 1953.

J. L. Barnes, E. M. McDowell, and J. S. McNeil, “Studies on the pathophysiology of acute renal failure. V. Effect of chronic saline loading on the progression of proximal tubular injury and functional impairment following administration of mercuric chloride in the rat,” Virchows Archiv Abteilung B Cell Pathology, vol. 32, no. 3, pp. 233–260, 1980.

G. de Vos, S. Abotaga, Z. Liao, E. Jerschow, and D. Rosenstreich, “Selective effect of mercury on Th2-type cytokine production in humans,” Immunopharmacology and Immunotoxicology, vol. 29, no. 3-4, pp. 537–548, 2007.

N. G. Ilback, J. Sundberg, and A. Oskarsson, “Methyl mercury exposure via placenta and milk impairs natural killer (NK) cell function in newborn rats,” Toxicology Letters, vol. 58, no. 2, pp. 149–158, 1991.

D. G. Ellingsen, J. Efskind, E. Haug, Y. Thomassen, I. Martinsen, and P. I. Gaarder, “Effects of low mercury vapour exposure on the thyroid function in chloralkali workers,” Journal of Applied Toxicology, vol. 20, no. 6, pp. 483–489, 2000.

M. V. Rao and P. S. N. Sharma, “Protective effect of vitamin E against mercuric chloride reproductive toxicity in male mice,” Reproductive Toxicology, vol. 15, no. 6, pp. 705–712, 2001.

E. Nadorfy-Lopez, S. H. Torres, H. Finol, M. Mendez, and B. Bello, “Skeletal muscle abnormalities associated with occupational exposure to mercury vapours,” Histology and Histopathology, vol. 15, no. 3, pp. 673–682, 2000.

D. W. Gruenwedel and D. S. Lu, “Changes in the sedimentation characteristics of DNA due to methylmercuration,” Biochemical and Biophysical Research Communications, vol. 40, no. 3, pp. 542–548, 1970.

S. P. Herman, R. Klein, F. A. Talley, and M. R. Krigman, “An ultrastructural study of methylmercury-induced primary sensory neuropathy in the rat,” Laboratory Investigation, vol. 28, no. 1, pp. 104–118, 1973.

B. A. Fowler and J. S. Woods, “Ultrastructural and biochemical changes in renal mitochondria during chronic oral methyl mercury exposure. The relationship to renal function,” Experimental and Molecular Pathology, vol. 27, no. 3, pp. 403–412, 1977.

G. Olivieri, C. Brack, F. Müller-Spahn et al., “Mercury induces cell cytotoxicity and oxidative stress and increases β- amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells,” Journal of Neurochemistry, vol. 74, no. 1, pp. 231–236, 2000.

S. Yee and B. H. Choi, “Oxidative stress in neurotoxic effects of methylmercury poisoning,” NeuroToxicology, vol. 17, no. 1, pp. 17–26, 1996.

N. G. Ilback, J. Sundberg, and A. Oskarsson, “Methyl mercury exposure via placenta and milk impairs natural killer (NK) cell function in newborn rats,” Toxicology Letters, vol. 58, no. 2, pp. 149–158, 1991.

S. H. Park, S. Araki, A. Nakata et al., “Effects of occupational metallic mercury vapour exposure on suppressor-inducer (CD4+CD45RA+) T lymphocytes and CD57+CD16+ natural killer cells,” International Archives of Occupational and Environmental Health, vol. 73, no. 8, pp. 537–542, 2000.

L. Santarelli, M. Bracci, and E. Mocchegiani, “In vitro and in vivo effects of mercuric chloride on thymic endocrine activity, NK and NKT cell cytotoxicity, cytokine profiles (IL-2, IFN-γ, IL-6): role of the nitric oxide-l-arginine pathway,” International Immunopharmacology, vol. 6, no. 3, pp. 376–389, 2006.

L. Vimercati, L. Santarelli, G. Pesola et al., “Monocyte-macrophage system and polymorphonuclear leukocytes in workers exposed to low levels of metallic mercury,” Science of the Total Environment, vol. 270, no. 1–3, pp. 157–163, 2001.

G. de Vos, S. Abotaga, Z. Liao, E. Jerschow, and D. Rosenstreich, “Selective effect of mercury on Th2-type cytokine production in humans,” Immunopharmacology and Immunotoxicology, vol. 29, no. 3-4, pp. 537–548, 2007.

T. Tanigawa, H. Takehashi, and A. Nakata, “Naïve (CD4+CD45RA+) T cell subpopulation is susceptible to various types of hazardous substances in the workplace,” International journal of immunopathology and pharmacology, vol. 17, supplement 2, pp. 109–114, 2004.

D. W. Gruenwedel and M. K. Cruickshank, “Effect of methylmercury(II) on the synthesis of deoxyribonucleic acid, ribonucleic acid and protein in HeLa S3 cells,” Biochemical Pharmacology, vol. 28, no. 5, pp. 651–655, 1979.

L. Friberg and G. F. Nordberg, Eds., Mercury in the Environment, CRC Press, Boca Raton, Fla, USA, 1972.

A. Andersen, D. G. Ellingsen, T. Morland, and H. Kjuus, “A neurological and neurophysiological study of chloralkali workers previously exposed to mercury vapour,” Acta Neurologica Scandinavica, vol. 88, no. 6, pp. 427–433, 1993.

P. J. Smith, G. D. Langolf, and J. Goldberg, “Effects of occupational exposure to elemental mercury on short term memory,” British Journal of Industrial Medicine, vol. 40, no. 4, pp. 413–419, 1983.

A. Cavalleri, L. Belotti, F. Gobba, G. Luzzana, P. Rosa, and P. Seghizzi, “Colour vision loss in workers exposed to elemental mercury vapour,” Toxicology Letters, vol. 77, no. 1–3, pp. 351–356, 1995.

D. Echeverria, N. J. Heyer, M. D. Martin, C. A. Naleway, J. S. Woods, and A. C. Bittner Jr., “Behavioral effects of low-level exposure to Hg∘ among dentists,” Neurotoxicology and Teratology, vol. 17, no. 2, pp. 161–168, 1995.

C. Kosan, A. K. Topaloglu, and B. Ozkan, “Chronic mercury intoxication simulating pheochromocytoma: effect of captopril on urinary mercury excretion,” Pediatrics International, vol. 43, no. 4, pp. 429–430, 2001.

R. L. Siblerud, J. Motl, and E. Kienholz, “Psychometric evidence that mercury from silver dental fillings may be an etiological factor in depression, excessive anger, and anxiety,” Psychological Reports, vol. 74, no. 1, pp. 67–80, 1994.

J. T. Salonen, K. Seppanen, K. Nyyssonen et al., “Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in Eastern Finnish men,” Circulation, vol. 91, no. 3, pp. 645–655, 1995.

H. M. Chan and G. M. Egeland, “Fish consumption, mercury exposure, and heart diseases,” Nutrition Reviews, vol. 62, no. 2, pp. 68–72, 2004.

S. Booth and D. Zeller, “Mercury, food webs, and marine mammals: implications of diet and climate change for human health,” Environmental Health Perspectives, vol. 113, no. 5, pp. 521–526, 2005.

P. Grandjean, P. Weihe, R. F. White et al., “Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury,” Neurotoxicology and Teratology, vol. 19, no. 6, pp. 417–428, 1997.

G. B. Ramirez, O. Pagulayan, H. Akagi et al., “Tagum study II: follow-up study at two years of age after prenatal exposure to mercury,” Pediatrics, vol. 111, no. 3, pp. 289–295, 2003.

A. Aitio, S. Valkonen, H. Kivisto, and E. Yrjanheikki, “Effect of occupational mercury exposure on plasma lysosomal hydrolases,” International Archives of Occupational and Environmental Health, vol. 53, no. 2, pp. 139–147, 1983.

M. Berlin, J. Fazackerley, and G. Nordberg, “The uptake of mercury in the brains of mammals exposed to mercury vapor and to mercuric salts,” Archives of Environmental Health, vol. 18, no. 5, pp. 719–729, 1969.

M. Berlin and S. Gibson, “Renal uptake, excretion, and retention of mercury. I. A study in the rabbit during infusion of mercuric chloride,” Archives of Environmental Health, vol. 6, pp. 617–625, 1963.

G. Drasch, E. Wanghofer, and G. Roider, “Are blood, urine, hair, and muscle valid biomonitors for the internal burden of men with the heavy metals mercury, lead and cadmium? An investigation on 150 deceased,” Trace Elements in Medicine, vol. 14, no. 3, pp. 116–123, 1997.

R. G. Smith, A. J. Vorwald, L. S. Patil, and T. F. Mooney, “Effects of exposure to mercury in the manufacture of chlorine,” American Industrial Hygiene Association journal, vol. 31, no. 6, pp. 687–700, 1970.

“3rd National report on human exposure to environmental chemicals,” Tech. Rep., Centers for Disease Control and Prevention, 2005.

M. W. Haut, L. A. Morrow, D. Pool, T. S. Callahan, J. S. Haut, and M. D. Franzen, “Neurobehavioral effects of acute exposure to inorganic mercury vapor,” Applied Neuropsychology, vol. 6, no. 4, pp. 193–200, 1999.

D. B. Chaffin, D. B. Dinman, J. M. Miller, et al., “Final report NIOSH,” Tech. Rep. contract no HSM-099-71-62, University of Michigan, Ann Arbor, Mich, USA, 1973.

M. Meyer-Baron, M. Schaeper, and A. Seeber, “A meta-analysis for neurobehavioural results due to occupational mercury exposure,” Archives of Toxicology, vol. 76, no. 3, pp. 127–136, 2002.

R. Lucchini, I. Cortesi, P. Facco et al., “Neurotoxic effect of exposure to low doses of mercury,” Medicina del Lavoro, vol. 93, no. 3, pp. 202–214, 2002.

D. Echeverria, H. Vasken Aposhian, J. S. Woods et al., “Neurobehavioral effects from exposure to dental amalgam Hg⁰: new distinctions between recent exposure and Hg body burden,” FASEB Journal, vol. 12, no. 11, pp. 971–980, 1998.

H. A. Roels, P. Hoet, and D. Lison, “Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risks of nephrotoxicity,” Renal Failure, vol. 21, no. 3-4, pp. 251–262, 1999.

D. C. Rice, “The US EPA reference dose for methylmercury: sources of uncertainty,” Environmental Research, vol. 95, no. 3, pp. 406–413, 2004.

G. Kazantzis, “Mercury exposure and early effects: an overview,” Medicina del Lavoro, vol. 93, no. 3, pp. 139–147, 2002.

H. V. Aposhian, A. Arroyo, M. E. Cebrian et al., “DMPS-arsenic challenge test. I: increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate,” Journal of Pharmacology and Experimental Therapeutics, vol. 282, no. 1, pp. 192–200, 1997.

G. Kazantzis, “Diagnosis and treatment of metal poisoning—general aspects,” in Handbook on The Toxicology of Metals, G. F. Nordberg, Ed., chapter 15, pp. 313–314, Elsevier, New York, NY, USA, 3rd edition, 2007.

V. R. Schiele, K. H. Schaller, and D. Weltle, “Aus dem Institut fur Arbeits-und Sozialmedizin und der Poliklinik fur Berufskrankheiten de Universitat Erlangen-Nurnberg,” pp. 249–251, 1989.

M. Godfrey and N. Campbell, “Confirmation of mercury retention and toxicity using 2,3 dimercapto-1-propane sulphonic acid sodium salt (DMPS),” Journal of Advancement in Medicine, vol. 7, no. 1, pp. 19–30, 1994.

M. Daunderer, “Mobilization test for environmental metal poisonings,” Forum des Praktischen und Allgemein-Arztes, vol. 28, no. 3, pp. 88–94, 1989.

M. Molin, A. Schutz, S. Skerfving, and G. Sallsten, “Mobilized mercury in subjects with varying exposure to elemental mercury vapour,” International Archives of Occupational and Environmental Health, vol. 63, no. 3, pp. 187–192, 1991.

J. Aaseth, D. Jacobsen, O. Andersen, and E. Wickstrom, “Treatment of mercury and lead poisonings with dimercaptosuccinic acid and sodium dimercaptopropanesulfonate. A review,” Analyst, vol. 120, no. 3, pp. 853–854, 1995.

O. Torres-Alanis, L. Garza-Ocanas, and A. Pineyro-Lopez, “Evaluation of urinary mercury excretion after administration of 2,3-dimercaptol-propane sulfonic acid to occupationally exposed men,” Journal of Toxicology—Clinical Toxicology, vol. 33, no. 6, pp. 717–720, 1995.

H. V. Aposhian, R. M. Maiorino, M. Rivera et al., “Human studies with the chelating agents, DMPS and DMSA,” Journal of Toxicology—Clinical Toxicology, vol. 30, no. 4, pp. 505–528, 1992.

R. M. Maiorino, R. C. Dart, D. E. Carter, and H. V. Aposhian, “Determination and metabolism of dithiol chelating agents. XII. Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans,” Journal of Pharmacology and Experimental Therapeutics, vol. 259, no. 2, pp. 808–814, 1991.

K. M. Hurlbut, R. M. Maiorino, M. Mayersohn, R. C. Dart, D. C. Bruce, and H. V. Aposhian, “Determination and metabolism of dithiol chelating agents XVI: pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers,” Journal of Pharmacology and Experimental Therapeutics, vol. 268, no. 2, pp. 662–668, 1994.

H. V. Aposhian, “Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate (DMPS),” Environmental Health Perspectives, vol. 106, no. 4, pp. 1017–1025, 1998.

H. V. Aposhian, R. M. Maiorino, D. Gonzalez-Ramirez et al., “Mobilization of heavy metals by newer, therapeutically useful chelating agents,” Toxicology, vol. 97, no. 1–3, pp. 23–38, 1995.

“2,3 Dimercapto-1-propane sulfonic acid (DMPS) in the treatment of heavy metal poisoning,” FDA Docket 98-n-0182 entry for DMPS and Nguyen H. T., 1999, http://www.fda.gov/ohrms/dockets/DOCKETS/98n0182/nom005b.pdf

G. Sallsten, L. Barregard, and A. Schutz, “Clearance half life of mercury in urine after the cessation of long term occupational exposure: influence of a chelating agent (DMPS) on excretion of mercury in urine,” Occupational and Environmental Medicine, vol. 51, no. 5, pp. 337–342, 1994.

O. Torres-Alanis, L. Garza-Ocanas, and A. Pineyro-Lopez, “Evaluation of urinary mercury excretion after administration of 2,3-dimercaptol-propane sulfonic acid to occupationally exposed men,” Journal of Toxicology—Clinical Toxicology, vol. 33, no. 6, pp. 717–720, 1995.

D. Gonzalez-Ramirez, M. Zuniga-Charles, A. Narro-Juarez et al., “DMPS (2,3-dimercaptopropane-1-sulfonate, dimaval) decreases the body burden of mercury in humans exposed to mercurous chloride,” Journal of Pharmacology and Experimental Therapeutics, vol. 287, no. 1, pp. 8–12, 1998.

S. Böse-O'Reilly, G. Drasch, C. Beinhoff et al., “The Mt. Diwata study on the Philippines 2000—Treatment of mercury intoxicated inhabitants of a gold mining area with DMPS (2,3-Dimercapto-1-propane-sulfonic acid, Dimaval®),” Science of the Total Environment, vol. 307, no. 1–3, pp. 71–82, 2003.

G. Drasch, S. Böse-O'Reilly, C. Beinhoff, G. Roider, and S. Maydl, “The Mt. Diwata study on the Philippines 1999—Assessing mercury intoxication of the population by small scale gold mining,” Science of the Total Environment, vol. 267, no. 1–3, pp. 151–168, 2001.

J. R. Campbell, T. W. Clarkson, and M. D. Omar, “The therapeutic use of 2,3-dimercaptopropane-1-sulfonate in two cases of inorganic mercury poisoning,” Journal of the American Medical Association, vol. 256, no. 22, pp. 3127–3130, 1986.

J. C. Pendergrass, B. E. Haley, M. J. Vimy, S. A. Winfield, and F. L. Lorscheider, “Mercury vapor inhalation inhibits binding of GTP to tubulin in rat brain: similarity to a molecular lesion in Alzheimer diseased brain,” NeuroToxicology, vol. 18, no. 2, pp. 315–324, 1997.

M. Fujimura, F. Usuki, M. Sawada, and A. Takashima, “Methylmercury induces neuropathological changes with tau hyperphosphorylation mainly through the activation of the c-jun-N-terminal kinase pathway in the cerebral cortex, but not in the hippocampus of the mouse brain,” NeuroToxicology, vol. 30, no. 6, pp. 1000–1007, 2009.

F. Monnet-Tschudi, M. G. Zurich, C. Boschat, A. Corbaz, and P. Honegger, “Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases,” Reviews on Environmental Health, vol. 21, no. 2, pp. 105–117, 2006.

M. Aschner, N. Onishchenko, and S. Ceccatelli, “Toxicology of alkylmercury compounds,” Metal Ions in Life Sciences, vol. 7, pp. 403–423, 2010.

J. Mutter, A. Curth, J. Naumann, R. Deth, and H. Walach, “Does inorganic mercury play a role in Alzheimer's disease? A systematic review and an integrated molecular mechanism,” Journal of Alzheimer's Disease, vol. 22, no. 2, pp. 357–374, 2010.

F. O. Johnson and W. D. Atchison, “The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis,” NeuroToxicology, vol. 30, no. 5, pp. 761–765, 2009.

D. J. Yang, S. Shi, L. F. Zheng, T. M. Yao, and L. N. Ji, “Mercury(II) promotes the in vitro aggregation of tau fragment corresponding to the second repeat of microtubule-binding domain: coordination and conformational transition,” Biopolymers, vol. 93, no. 12, pp. 1100–1107, 2010.

“(NHANES III) 3rd National report on human exposure to environmental chemicals,” Tech. Rep., Centers for Disease Control and Prevention, 2005.

“(NHANES IV) 4th National Report on Human Exposure to Environmental Chemicals,” Tech. Rep., Centers for Disease Control and Prevention, 2009.

“Toxicological profile for mercury,” U.S. Department of Health and Human Services, Public Health Service, 1999, http://www.atsdr.cdc.gov/toxprofiles/tp46.pdf

“Diagnostic and Treatment Protocols for safer, effective mercury human biohazard management,” Consensus Development Working Group of the International College of Integrative Medicine, 2003.

Chelation Module, American College for Advancement in Medicine, Irvine, Calif, USA, 2010.

Advanced Medical Education and Services Physician Association, Introduction to Clinical Metal Toxicology, Advanced Medical Education and Services Physician Association, San Antonio, Tex, USA, 2007.

Clinician Seminar Level 1, Autism Research Institute, San Diego, Calif, USA, 2010.

R. A. Bernhoft and R. A. Buttar, “Autism: a multi-system oxidative and inflammatory disorder,” Townsend Letter, pp. 86–90, 2008.